{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:51:57Z","timestamp":1778644317383,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013709","name":"University of Texas at Austin Dell Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013709","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bpobgyn.2025.102682","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T08:03:56Z","timestamp":1761638636000},"page":"102682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Biologics in red cell and platelet alloimmunizations: State of the science and future perspectives"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5028-8426","authenticated-orcid":false,"given":"Kenneth J.","family":"Moise Jr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonor","family":"Tiblad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2025.102682_bib1","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1182\/bloodadvances.2023012241","article-title":"Maternal red blood cell alloimmunization prevalence in the United States","volume":"8","author":"Sugrue","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/AOG.0000000000005692","article-title":"Cell-free DNA analysis for the determination of fetal red blood cell antigen genotype in individuals with alloimmunized pregnancies","volume":"144","author":"Rego","year":"2024","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/AOG.0000000000005709","article-title":"Management of red cell alloimmunization in pregnancy","volume":"144","author":"Moise","year":"2024","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/bmj.2.5365.1107","article-title":"Intrauterine transfusion of foetus in haemolytic disease","volume":"2","author":"Liley","year":"1963","journal-title":"Br Med J"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/uog.17319","article-title":"Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures","volume":"50","author":"Zwiers","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(85)92451-1","article-title":"Rhesus haemolytic disease treated with high-dose intravenous immunoglobulin [letter]","volume":"1","author":"Berlin","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM198802253180816","article-title":"High-dose intravenous immunoglobulin as the sole prenatal treatment for severe Rh immunization","volume":"318","author":"de la Camara","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib8","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/j.ajog.2018.06.007","article-title":"Postponing early intrauterine transfusion with Intravenous immunoglobulin treatment; the PETIT study on severe hemolytic disease of the fetus and newborn","volume":"219","author":"Zwiers","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.18449","article-title":"Intravenous immunoglobulin in the management of severe early onset red blood cell alloimmunisation","volume":"200","author":"Vlachodimitropoulou","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ajog.2024.03.044","article-title":"Intravenous immunoglobulin for the treatment of severe maternal alloimmunization: individual patient data meta-analysis","volume":"231","author":"Mustafa","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib11","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jaip.2023.04.002","article-title":"Intravenous immunoglobulin: mechanism of action in autoimmune and inflammatory conditions","volume":"11","author":"Bayry","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3109\/00016349509021196","article-title":"Alloimmunization during pregnancy treated with high dose intravenous immunoglobulin. Effects on fetal hemoglobin concentration and anti-D concentrations in the mother and fetus","volume":"74","author":"Gottvall","year":"1995","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fimmu.2015.00176","article-title":"Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human Primates","volume":"6","author":"Nixon","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib17","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 Vivacity-MG study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF01720276","article-title":"IgG replacement therapy for primary hypogammaglobulinaemia during pregnancy: report of 9 pregnancies in 4 patients","volume":"60","author":"Williams","year":"1990","journal-title":"Blut"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib19","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1021\/bi052628y","article-title":"Albumin binding to FcRn: distinct from the FcRn-IgG interaction","volume":"45","author":"Chaudhury","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1471-0528.1993.tb15315.x","article-title":"The intravascular mass of albumin during human pregnancy: a serial study in normal and diabetic women","volume":"100","author":"Whittaker","year":"1993","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib21","doi-asserted-by":"crossref","first-page":"e1491","DOI":"10.1016\/j.ajog.2019.02.058","article-title":"M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model","volume":"220","author":"Roy","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/clpt.2011.66","article-title":"The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs","volume":"90","author":"Hutson","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib23","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an Anti-FcRn antibody: Pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200001063420102","article-title":"Noninvasive diagnosis by doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization","volume":"342","author":"Mari","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib25","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/1471-0528.12063","article-title":"Increased perinatal loss after intrauterine transfusion for alloimmune anaemia before 20 weeks of gestation","volume":"120","author":"Lindenburg","year":"2013","journal-title":"BJOG"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJMoa2314466","article-title":"Nipocalimab in early onset severe hemolytic disease of the fetus and newborn","volume":"391","author":"Moise","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib27","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/a-2404-8089","article-title":"Design of a phase 3, global, multicenter, randomized, placebo-controlled, double-blind study of nipocalimab in pregnancies at risk for severe hemolytic disease of the fetus and newborn","volume":"42","author":"Komatsu","year":"2025","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.tmrv.2020.09.004","article-title":"Fetal and neonatal alloimmune thrombocytopenia-new prospects for fetal risk assessment of HPA-1a-Negative pregnant women","volume":"34","author":"Kjeldsen-Kragh","year":"2020","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib29","author":"Calandrini","year":"2024","journal-title":"Vox Sang"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2019.102704","article-title":"Epidemiology and management of fetal and neonatal alloimmune thrombocytopenia","volume":"59","author":"de Vos","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0308-2261(21)00573-7","article-title":"Neonatal thrombocytopenia","volume":"7","author":"Pearson","year":"1978","journal-title":"Clin Haematol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/01.AOG.0000270302.80336.dd","article-title":"Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial","volume":"110","author":"Berkowitz","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib33","doi-asserted-by":"crossref","first-page":"135 e131","DOI":"10.1016\/j.ajog.2010.03.011","article-title":"Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus","volume":"203","author":"Bussel","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib34","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/AOG.0b013e31823403f4","article-title":"Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification","volume":"118","author":"Pacheco","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2025.102682_bib35","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1016\/S2352-3026(25)00029-8","article-title":"Rising to the challenge: an international Delphi consensus study on fetal and neonatal alloimmune thrombocytopenia","volume":"12","author":"Pothof","year":"2025","journal-title":"Lancet Haematol"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693425001063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693425001063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T16:40:54Z","timestamp":1764780054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693425001063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"alternative-id":["S1521693425001063"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2025.102682","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics in red cell and platelet alloimmunizations: State of the science and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2025.102682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102682"}}